Novel MOAs and targets for cancer drug development What s hot off the presses?

Size: px
Start display at page:

Download "Novel MOAs and targets for cancer drug development What s hot off the presses?"

Transcription

1 Novel MOAs and targets for cancer drug development What s hot off the presses? Moderator: Jeremy Goldberg, President, JPG Healthcare LLC Panelists: Robert J Schneider, PhD, Associate Director, NYU Cancer Institute Director, Translational Cancer Research Co-director, Breast Cancer Research Program Paul B. Fisher, MPh, PhD, Professor and Chairman, Department of Human & Molecular Genetics, Founding Director, VCU Institute of Molecular Medicine, VCU School of Medicine, Thelma Newmeyer Corman Chair in Cancer Research, VCU Massey Cancer Center Carlo M. Croce, MD, The John W. Wolfe Chair in Human Cancer Genetics, The Ohio State University, Chairman, Dept. of Molecular Virology, Immunology and Medical Genetics, Director, Institute of Genetics Philip W. Kantoff, MD, Chief Clinical Research Officer, Chief, Division of Solid Tumor Oncology, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School

2 Impediments to Effective Systemic Oncolytic Viral Therapy of Cancer: A Fixable Problem? Inefficient transduction and lack of true cancer-specific targeting Viral replication alone does not work: bipartite viral approach (mda-7/il-24) Trapping of virus in the liver and immune clearance of the therapeutic ti virus Answer: Cancer Terminator Virus (CTV)

3 The PEG-3 Promoter Targets GFP Transgene Expression in Breast Cancers and Malignant Gliomas Breast Cancers Malignant Gliomas HMEC: Primary Human Breast Epithelial Cells PHFA: Primary Human Fetal Astrocytes

4 Cancer Terminator Viruses (M7-CTV): Conditional Viral Replication + Cancer- Selective Apoptosis, Immune Targeting PEG-PromProm E1A + E1B CMV-Prom mda-7/il-24 Conditionally Replication-Competent Adenovirus Normal Cells: No effect Primary and Distant Tumor Cells: Apoptosis, Immune Destruction

5 M7-CTV (mda-7/il-24) ) Cures Mice Containing Established Metastatic M12 Intraperitoneal Tumors Ad.vec Ad.PEG-E1A Ad.PEG-M7 M7-CTV (mda-7)

6 Tropism Modified Cancer Terminator Viruses (Ad.5/3-CTV) CTV): : An Improved CTV PEG-PromProm E1A + E1B CMV-Prom mda-7/il-24 Ad.5/3 Conditionally Replication-Competent Ad (Ad.5/3-CTV) Normal Cells: No effect Primary and Distant Tumor Cells: Apoptosis, Immune Destruction

7 Effect of Ad.5/3-CTV in Primary Human GBM6 Growing in Mouse Brains

8 Profound Therapeutic Activity of Ad.5/3-CTV in Primary GBM Grown in Mouse Brains

9 Breakthrough Treatment with Cancer Terminator Virus (CTV) Systemic Terminator Virus attacks distal tumors and cycle repeats Normal Cell Inject Terminator Virus -IV (Microbubble) -intra-tumoral t -intra-peritoneal Terminator Virus mda-7/il-24 Immune Response Oncolytic Cell Death & mda-7/il-24-stimulated Anti-Tumor Immune Response Cancer Cell

10 Ultrasound-Targeted Microbubble Delivery of CTV

11

12 Novel MOAs and targets for cancer drug development What s hot off the presses? Moderator: Jeremy Goldberg, President, JPG Healthcare LLC Panelists: Robert J Schneider, PhD, Associate Director, NYU Cancer Institute Director, Translational Cancer Research Co-director, Breast Cancer Research Program Paul B. Fisher, MPh, PhD, Professor and Chairman, Department of Human & Molecular Genetics, Founding Director, VCU Institute of Molecular Medicine, VCU School of Medicine, Thelma Newmeyer Corman Chair in Cancer Research, VCU Massey Cancer Center Carlo M. Croce, MD, The John W. Wolfe Chair in Human Cancer Genetics, The Ohio State University, Chairman, Dept. of Molecular Virology, Immunology and Medical Genetics, Director, Institute of Genetics Philip W. Kantoff, MD, Chief Clinical Research Officer, Chief, Division of Solid Tumor Oncology, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School

13 Novel MOAs and targets for cancer drug development What s hot off the presses? Discussion Points Dr. Philip Kantoff successes & challenges for new prostate cancer therapeutics androgen pathway inhibitors, bone targeting agents, Provenge immunotherapy Dr. Carlo Croce role of micro RNAs in Prognostic, Diagnostic, Therapeutic approaches to cancer Dr. Bob Schneider design of early clinical trials for mtor inhibitors, targeting protein synthesis and targeting oncogenic mrna Dr. Paul Fisher future of gene therapy in cancer therapeutic viruses, delivery, theranostics

23 rd Annual Cancer Progress Conference

23 rd Annual Cancer Progress Conference 23 rd Annual Cancer Progress Conference March 6 & 7, 2012 The Westin New York at Times Square AGENDA Tuesday, March 6, 2012 7:00am Continental Breakfast and Registration- Majestic Foyer 8:15-8:45am Opening

More information

New Treatment Options for Prostate Cancer

New Treatment Options for Prostate Cancer New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer

More information

Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic

Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic /, Vol. 6, No. 13 Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic Siddik Sarkar 1, Bridget A. Quinn 1, Xue-Ning Shen 1, Rupesh Dash 2, Swadesh K. Das

More information

Exploring Immunotherapies: Beyond Checkpoint Inhibitors

Exploring Immunotherapies: Beyond Checkpoint Inhibitors Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction

More information

For personal use only

For personal use only Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. ICH Considerations

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. ICH Considerations INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations General Principles to Address Virus and Vector Shedding 1.0 Introduction

More information

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response

More information

Radiation and Immunotherapy

Radiation and Immunotherapy Radiation and Immunotherapy What s it All About? Encouse Golden, MD, PhD Assistant Professor of Radiation Oncology 10.25.16 www.weillcornell.org Silvia Formenti, MD Chairman of Radiation Oncology, Sandra

More information

Vaccine Therapy for Cancer

Vaccine Therapy for Cancer Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence

More information

Oncolytic virus strategy

Oncolytic virus strategy Oncolytic viruses Oncolytic virus strategy normal tumor NO replication replication survival lysis Oncolytic virus strategy Mechanisms of tumor selectivity of several, some of them naturally, oncolytic

More information

8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina

8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina FIRST ANNOUNCEMENT 8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina The 8 th Conference of IAOC "Current

More information

Experimental Therapeutics I

Experimental Therapeutics I Experimental Therapeutics I Mary Hitt 5142 Katz Group Centre mhitt@ualberta.ca; or Mary.Hitt@albertahealthservices.ca 1 Specific Topics for Today Preclinical and clinical testing Gene therapy Nonviral

More information

Coxsackievirus A21 as an oncolytic agent for the control of human cancer

Coxsackievirus A21 as an oncolytic agent for the control of human cancer Coxsackievirus A21 as an oncolytic agent for the control of human cancer Dr Gough G. Au PhD Conjoint Research Fellow The University of Newcastle Australia Viralytics Ltd. Viruses can be used to treat cancer

More information

David L. Bartlett, M.D. University of Pittsburgh

David L. Bartlett, M.D. University of Pittsburgh A Phase I Dose-Escalation Trial of vvdd- CDSR (Double-Deleted Vaccinia Virus Plus CD/SMR) Administered by Intratumoral Injection in Patients with Superficial Injectable Tumors David L. Bartlett, M.D. University

More information

Micro RNA Research. Ken Kosik. Harriman Professor, Department of Molecular, Cellular & Developmental Biology and Biomolecular Sciences & Engr.

Micro RNA Research. Ken Kosik. Harriman Professor, Department of Molecular, Cellular & Developmental Biology and Biomolecular Sciences & Engr. Ken Kosik Harriman Professor, Department of Molecular, Cellular & Developmental Biology and Biomolecular Sciences & Engr. Program Co-Director, Neurosciences Research Institute Micro RNA Research Neuroscience

More information

Radiotherapy Of Prostate Cancer

Radiotherapy Of Prostate Cancer Radiotherapy Of Prostate Cancer 1 / 6 2 / 6 3 / 6 Radiotherapy Of Prostate Cancer We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized

More information

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate AD Award Number: DAMD17-03-1-0163 TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate PRINCIPAL INVESTIGATOR: Robert Reiter, M.D. CONTRACTING ORGANIZATION: The

More information

The Wistar Institute is an international leader in biomedical

The Wistar Institute is an international leader in biomedical A LEADER IN RESEARCH The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology and infectious disease research. The Institute works actively to

More information

Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)

Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK) Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start

More information

Intrinsic cellular defenses against virus infection

Intrinsic cellular defenses against virus infection Intrinsic cellular defenses against virus infection Detection of virus infection Host cell response to virus infection Interferons: structure and synthesis Induction of antiviral activity Viral defenses

More information

Course Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins, Ph.D., The Houston Methodist Research Institute

Course Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins, Ph.D., The Houston Methodist Research Institute Saturday, August 20 25 th ANNUAL SHORT COURSE ON EXPERIMENTAL MODELS OF HUMAN CANCER August 20-28, 2016 Course Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins,

More information

Oncolytic viruses for cancer treatment

Oncolytic viruses for cancer treatment Oncolytic viruses for cancer treatment Interdisciplinary Technical Journal Club: Special Series on Laboratory Animal Science Dr. Katrin Frauenknecht Institute of Neuropathology University Hospital Zurich

More information

Oncolytic Virotherapy Summit Novel stroma targeted and microenvironment-inducible oncolytic adenoviruses (OAVs)

Oncolytic Virotherapy Summit Novel stroma targeted and microenvironment-inducible oncolytic adenoviruses (OAVs) Oncolytic Virotherapy Summit 2016 Novel stroma targeted and microenvironment-inducible oncolytic adenoviruses (OAVs) Osvaldo L. Podhajcer, Ph.D. Superior Researcher CONICET (Consejo Nacional de Investigaciones

More information

Atul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto

Atul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto TIME PROGRAM TITLE 7:30 8:15 Registration and Continental Breakfast 8:15 8:30 Welcoming Remarks TOPIC: VIRUSES Session Chair: Shahid Husain CMV: What is New, What s Hot Atul Humar, MD, MSc Director, Transplant

More information

GRANT RECIPIENT! Congratulations! 2017 We Care Fund Grant Recipient. Amanda L. Kong, MD, MS. Associate Professor, Division of Surgical Oncology

GRANT RECIPIENT! Congratulations! 2017 We Care Fund Grant Recipient. Amanda L. Kong, MD, MS. Associate Professor, Division of Surgical Oncology Congratulations! 2017 We Care Fund Grant Recipient GRANT Amanda L. Kong, MD, MS Associate Professor, Division of Surgical Oncology GRANT GRANT Prevention of Side Effects in Use of Chemotherapy in Breast

More information

25 th Annual Cancer Progress Conference March 4-5, 2014 New York

25 th Annual Cancer Progress Conference March 4-5, 2014 New York 25 th Annual Cancer Progress Conference March 4-5, 2014 New York AGENDA Tuesday, March 4, 2014 7:00-8:00am Registration and Continental Breakfast 8:00-8:15am Opening Remarks Jeff Bockman, PhD, VP, Defined

More information

JAY A. NELSON, PH.D. Executive Director and Vice President

JAY A. NELSON, PH.D. Executive Director and Vice President JAY A. NELSON, PH.D. Executive Director and Vice President TRANSLATING RESEARCH INTO HEALTH Jay A. Nelson, Ph.D., is the founder and Executive Director of Vaccine & Gene Therapy Institute of Florida (VGTI-FL)

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center. June 22-23, 2018

Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center. June 22-23, 2018 Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center June 22-23, 2018 Note: ** Indicates the activity has been approved for AMA PRA Category 1 Credit jointly provided

More information

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline High-Risk Disease

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline High-Risk Disease Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline High-Risk Disease Mary-Ellen Taplin, MD Associate Professor of Medicine Harvard Medical School Director of Clinical Research, Lank Center for

More information

Posters and Presentations

Posters and Presentations Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

17th Annual Aultman Regional CANCER SYMPOSIUM

17th Annual Aultman Regional CANCER SYMPOSIUM 17th Annual Aultman Regional CANCER SYMPOSIUM CONFERENCE CHAIR: David Litvak, M.D., MBA, FACS, Medical Director of Cancer Services 9 16 17 A SYMPOSIUM FOCUSING ON: A symposium focusing on current topics

More information

Update on cell therapy using dendritic cells

Update on cell therapy using dendritic cells Update on cell therapy using dendritic cells Prof. dr. Evelien Smits UAntwerp, 24 March 2017 evelien.smits@uza.be Hallmarks of cancer (Hanahan and Weinberg, Cell 2000) Hanahan and Weinberg, 2000 Extra

More information

Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center. June 22-23, 2018

Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center. June 22-23, 2018 Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center June 22-23, 2018 Note: ** Indicates the activity has been approved for AMA PRA Category 1 Credit jointly provided

More information

Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS

Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS Brain Cancer New Treatment Opportunities - Discovery of new pathways in brain cancers

More information

IN VIVO STUDIES ON VIRAL VIRULENCE

IN VIVO STUDIES ON VIRAL VIRULENCE IN VIVO STUDIES ON VIRAL VIRULENCE M.Phil student: Emily TSUI Supervisor: Professor Paul K.S Chan Department of Microbiology, CUHK Date: 15th Dec, 2014 Viral Virulence Capacity of a virus to cause disease

More information

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los

More information

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B Section Director: Cliff Bellone, Ph.D. Office: Doisy Hall - R 405 Phone: 577-8449 E-Mail: bellonec@slu.edu Lecturers: James Swierkosz, Ph.D. Office: Medical School Rm. 412 Phone: 577-8430 E-Mail: swierkoszje@slu.edu

More information

BIT 120. Copy of Cancer/HIV Lecture

BIT 120. Copy of Cancer/HIV Lecture BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations

More information

Luciferase (Firefly and Renilla) Expression Stable Cell Lines

Luciferase (Firefly and Renilla) Expression Stable Cell Lines Luciferase (Firefly and Renilla) Expression Stable Cell Lines Catalog # Product Amount HEK293 Host cell line SC002-Bsd SC002-Puro SC002-Neo SC002-GB SC002-GP SC002-RB SC002-RP SC020-Puro SC020-RP SC021-Puro

More information

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018 NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements

More information

VIRUSES AND CANCER Michael Lea

VIRUSES AND CANCER Michael Lea VIRUSES AND CANCER 2010 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

EAU 2009: US Study Shows No Mortality Benefit From Prostate Cancer Screening, But European Study Suggests There May Be One

EAU 2009: US Study Shows No Mortality Benefit From Prostate Cancer Screening, But European Study Suggests There May Be One From Medscape Medical News : www.medscape.com/viewarticle/589786 EAU 2009: US Study Shows No Mortality Benefit From Prostate Cancer Screening, But European Study Suggests There May Be One By Roxanne Nelson

More information

John Bell Centre for Innovative Cancer Therapeutics

John Bell Centre for Innovative Cancer Therapeutics Enhancing Oncolytic Virus Activity by Engineering of Artificial micrornas John Bell Centre for Innovative Cancer Therapeutics Affiliated with Affilié à 1 Oncolytic Viruses: A Therapy for Metastatic Cancers?

More information

A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications

A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications A Novel CTC-Detecting Technique Using TelomeScan and Its Clinical Applications Yasuo Urata CEO and President Oncolys BioPharma Inc. February 16, 2013 Telomere Length is a Limiting Factor for Cell Replication

More information

DUARTE, Calif. A team of City of Hope researchers has received a two-year, $1

DUARTE, Calif. A team of City of Hope researchers has received a two-year, $1 FOR IMMEDIATE RELEASE January 30, 2014 CONTACT H. Chung So / Roberta Nichols Phone: 800-888-5323 hso@coh.org / ronichols@coh.org $1 million Movember-Prostate Cancer Foundation Challenge Award will fund

More information

Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique

Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks

More information

Pioneering vaccines that transform lives.

Pioneering vaccines that transform lives. Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme

More information

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

Practice of Medicine-1 Ovarian Cancer Clinical Correlation Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by

More information

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK) The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold

More information

CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology

CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development

More information

CELL BIOLOGY - CLUTCH CH CANCER.

CELL BIOLOGY - CLUTCH CH CANCER. !! www.clutchprep.com CONCEPT: OVERVIEW OF CANCER Cancer is a disease which is primarily caused from misregulated cell division, which form There are two types of tumors - Benign tumors remain confined

More information

Breast Cancer Staging

Breast Cancer Staging Breast Cancer Staging Symposium on Best Practice in Recording Cancer Stage Royal College of Pathologists 10 June 2011 Dr Gill Lawrence, Director Tel: 0121 415 8129 Fax: 0121 414 7712 Email: gill.lawrence@wmciu.nhs.uk

More information

Call for Nominations. Opens: May 1, 2017 Deadline: September 30, 2017

Call for Nominations. Opens: May 1, 2017 Deadline: September 30, 2017 2018 Call for Nominations Opens: May 1, 2017 Deadline: September 30, 2017 About the Szent-Györgyi Prize for Progress in Cancer Research The Szent-Györgyi Prize for Progress in Cancer Research was established

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

YOUR DONATIONS MAKING A DIFFERENCE

YOUR DONATIONS MAKING A DIFFERENCE YOUR DONATIONS MAKING A DIFFERENCE Grant 2013 2013 $20,000 David Langenau, M.D. 2013 $20,000 Garrett M. Brodeur, M.D. 2013 $20,000 Loren Walensky, M.D., Ph.D. Massachusetts General Hospital, Boston, MA

More information

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,

More information

Build a better chicken?

Build a better chicken? Build a better chicken? Generation of transgenic chickens resistant to avian influenza virus. Dr. Laurence Tiley Dept. Clinical Veterinary Medicine University of Cambridge Prevention is better than cure.

More information

Cancer Vaccines and Combination Immunotherapy

Cancer Vaccines and Combination Immunotherapy Cancer Vaccines and Combination Immunotherapy Bernard A. Fox, PhD Harder Family Chair for Cancer Research Member and Chief, Laboratory of Molecular and Tumor Immunology Earle A. Chiles Research Institute

More information

Unlocking Innovation to Advance Cancer Care

Unlocking Innovation to Advance Cancer Care Unlocking Innovation to Advance Cancer Care Liz Barrett, Global President & General Manager, Oncology at Pfizer Remarks for Women in Government November 10, 2017 Addressing Significant Unmet Need About

More information

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING

More information

Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3

Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone

More information

Pro5 MHC Pentamers. Dr. Jeremy Fry. Copyright ProImmune Limited All Rights Reserved

Pro5 MHC Pentamers. Dr. Jeremy Fry. Copyright ProImmune Limited All Rights Reserved Pro5 MHC Pentamers Dr. Jeremy Fry Pro5 MHC Pentamers The most consistent technology for detecting antigenspecific T cells The most-cited commercially available MHC Multimer Used by most-leading academic

More information

Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer

Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer Khursheed Anwer, Ph.D. Executive Vice President and CSO Molecular Medicine

More information

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund December 2018 EXECUTIVE SUMMARY As a top-ranked pediatric cancer center, Dana-Farber Cancer Institute combines first-rate patient care with groundbreaking

More information

National Breast Cancer Audit next steps. Martin Lee

National Breast Cancer Audit next steps. Martin Lee National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast

More information

Viruses and cancer: Should we be more afraid?

Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development

More information

Gene Therapies. Josh Crockett, Lexi Trujillo, Caitlin Halliday

Gene Therapies. Josh Crockett, Lexi Trujillo, Caitlin Halliday Gene Therapies Josh Crockett, Lexi Trujillo, Caitlin Halliday Gene Therapy Main objective: create carriers that can envelope and deliver genetic materials into target tissues (like cancerous cells) in

More information

Oncolytic Virotherapy: Targeting Cancer Stem Cells

Oncolytic Virotherapy: Targeting Cancer Stem Cells Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:

More information

AGENDA: FEBRUARY 22, 2018 INTRODUCTION

AGENDA: FEBRUARY 22, 2018 INTRODUCTION FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop with support from Cancer Research UK Combinations Alliance February 22-23, 2018 Bethesda, MD Purpose: There is great interest

More information

Philip Kantoff, MD Dana-Farber Cancer Institute

Philip Kantoff, MD Dana-Farber Cancer Institute CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests

More information

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult

More information

Comprehensive Approach to Oral and Head & Neck Cancer. at the DRAFT PLANNING DOCUMENT

Comprehensive Approach to Oral and Head & Neck Cancer. at the DRAFT PLANNING DOCUMENT Comprehensive Approach to Oral and Head & Neck Cancer at the DRAFT PLANNING DOCUMENT 1 VCU Philips Institute for Oral & Craniofacial Molecular l Biology Vision i for the future Comprehensive Institute

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology Dedicated to Preventing and Treating Life-Threatening Viral Infections Randall Lanier Vice President, Biology Adenovirus: Epidemiology and Treatment Options Allogeneic hematopoietic cell transplant (allo

More information

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis. Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

More information

American Nuclear Society Annual Meeting Chicago, June 24-28, 2012 President s Special Session

American Nuclear Society Annual Meeting Chicago, June 24-28, 2012 President s Special Session American Nuclear Society Annual Meeting Chicago, June 24-28, 2012 President s Special Session LOW-LEVEL LEVEL RADIATION AND ITS IMPLICATIONS FOR FUKUSHIMA RECOVERY Radiation Oncology Kiyohiko Sakamoto

More information

Coxsackievirus A21: The basic facts

Coxsackievirus A21: The basic facts Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents

More information

VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON

VIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION

More information

Immunotherapy Overview, Rationale, and Role in Clinical Practice

Immunotherapy Overview, Rationale, and Role in Clinical Practice Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES

More information

AMEY 1. p53 Gene Therapy: A Novel Approach in the Treatment of Cancer

AMEY 1. p53 Gene Therapy: A Novel Approach in the Treatment of Cancer AMEY 1 p53 Gene Therapy: A Novel Approach in the Treatment of Cancer An Honors Thesis by: Suzanne C. Amey Advisor: Dr. Robert O Donnell May 2002 AMEY 2 Outline of Contents I. Introduction II. III. IV.

More information

Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (htert)

Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (htert) Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (htert) Eunhee Kim, Joo-Hang Kim, M.D., Ha-Youn Shin, Han Saem Lee, Joo-Hyuk Sohn, M.D., Jai Myung

More information

Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015

Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family

More information

Immunology CANCER IMMUNOLOGY

Immunology CANCER IMMUNOLOGY Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing

More information

Transcription and RNA processing

Transcription and RNA processing Transcription and RNA processing Lecture 7 Biology W3310/4310 Virology Spring 2016 It is possible that Nature invented DNA for the purpose of achieving regulation at the transcriptional rather than at

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Spandana Baruah December, 2016 Cancer is defined as: «A disease caused

More information

pplementary Figur Supplementary Figure 1. a.

pplementary Figur Supplementary Figure 1. a. pplementary Figur Supplementary Figure 1. a. Quantification by RT-qPCR of YFV-17D and YFV-17D pol- (+) RNA in the supernatant of cultured Huh7.5 cells following viral RNA electroporation of respective

More information

Speaker bios Chordoma Community Conference at MD Anderson Cancer Center

Speaker bios Chordoma Community Conference at MD Anderson Cancer Center Speaker bios Chordoma Community Conference at MD Anderson Cancer Center Fredrick Castellano, MBA Fred Castellano is the Director of Managed Care Contracting for The University of Texas MD Anderson Cancer

More information

[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011

[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 [ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events

More information

Lahore University of Management Sciences. BIO 314- Microbiology and Virology (Spring 2018)

Lahore University of Management Sciences. BIO 314- Microbiology and Virology (Spring 2018) BIO 314- Microbiology and Virology (Spring 2018) Instructor Shaper Mirza Room No. 9-318A Office Hours TBA Email Shaper.Mirza@uth.tmc.edu ; shaper.mirza@lums.edu.pk Telephone 8413 Secretary/TA No TA Office

More information

Division of Immunology 1 Blackfan Circle Boston, MA (617) Title: Orthopox Immunization in patients with cancer or eczema

Division of Immunology 1 Blackfan Circle Boston, MA (617) Title: Orthopox Immunization in patients with cancer or eczema Title: Orthopox Immunization in patients with cancer or eczema Principal Investigator: Ellis Rheinherz, MD Researchers Involved: Robert Fuhlbrigge MD, PhD Summary: The major goals of this Cooperative Center

More information

Dendritic Cell Based Cancer Vaccine Development

Dendritic Cell Based Cancer Vaccine Development Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM

More information

Recombinant Protein Expression Retroviral system

Recombinant Protein Expression Retroviral system Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential

More information

PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018

PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018 PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, 2018 16 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 12-15, 2018 Friday, January 12, 2018 Registration:

More information

Are Immune Modulators Really Needed to Cure HBV infection?

Are Immune Modulators Really Needed to Cure HBV infection? Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,

More information

Brian Brewer Cancer Research Institute WELCOME

Brian Brewer Cancer Research Institute WELCOME Brian Brewer Cancer Research Institute WELCOME Our Sponsors This event is made possible with generous support from: Our Educational Partners Thank you to those who helped promote the summit Addario Lung

More information

Summary of Evolution and the Requirements for the Specific Cure of Cancer

Summary of Evolution and the Requirements for the Specific Cure of Cancer Summary of Evolution and the Requirements for the Specific Cure of Cancer The definition of cancer Cancer is defined by malignant behavior, (e.g. cell proliferation and invasiveness in an abnormal context.

More information